FindTrial
Sign In

Prednison 10 mg GALEN®

DRUG3 trials

Sponsors

Seagen Inc., Kartos Therapeutics Inc., Priovant Therapeutics Inc.

Conditions

Peripheral T-cell LymphomaPrimary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) With Intermediate Or High-Risk TP53 Wild-Type (TP53 WT) Who Are Relapsed Or Refractory to Janus Kinase (JAK) - Inhibitor Treatmentactive non-infectious uveitis (intermediate uveitispanuveitis)posterior uveitis

Phase 2

C5691004 _ A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression
CompletedCTIS2023-509155-14-00
Seagen Inc.Peripheral T-cell Lymphoma
Start: 2021-06-10End: 2026-01-05Target: 69Updated: 2026-01-16
A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
Active, not recruitingCTIS2024-513912-89-00
Kartos Therapeutics Inc.Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) With Intermediate Or High-Risk TP53 Wild-Type (TP53 WT) Who Are Relapsed Or Refractory to Janus Kinase (JAK) - Inhibitor Treatment
Start: 2018-12-13Target: 253Updated: 2025-09-17

Phase 3

A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis
Active, not recruitingCTIS2024-515089-15-00
Priovant Therapeutics Inc.active non-infectious uveitis (intermediate uveitis, panuveitis), posterior uveitis
Start: 2025-02-28Target: 105Updated: 2025-12-18